Review



fibronectin inhibitor rgds peptide  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress fibronectin inhibitor rgds peptide
    Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or <t>RGDS</t> peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.
    Fibronectin Inhibitor Rgds Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 35 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibronectin+inhibitor+rgds+peptide/pm36465134-185-14-22?v=MedChemExpress
    Average 94 stars, based on 35 article reviews
    fibronectin inhibitor rgds peptide - by Bioz Stars, 2026-07
    94/100 stars

    Images

    1) Product Images from "Role of pericytes in the development of cerebral cavernous malformations."

    Article Title: Role of pericytes in the development of cerebral cavernous malformations.

    Journal: iScience

    doi: 10.1016/j.isci.2022.105642

    Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or RGDS peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.
    Figure Legend Snippet: Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or RGDS peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.

    Techniques Used: Immunohistochemistry, Staining, Confocal Microscopy



    Similar Products

    fibronectin inhibitor rgds peptide  (MedChemExpress)
    94
    MedChemExpress fibronectin inhibitor rgds peptide
    Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or <t>RGDS</t> peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.
    Fibronectin Inhibitor Rgds Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibronectin+inhibitor+rgds+peptide/pm36465134-185-14-22?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    fibronectin inhibitor rgds peptide - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier
    fibronectin binding inhibitor rgds peptide  (Cayman Chemical)
    90
    Cayman Chemical fibronectin binding inhibitor rgds peptide
    Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or <t>RGDS</t> peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.
    Fibronectin Binding Inhibitor Rgds Peptide, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/fibronectin+inhibitor+rgds+peptide/10__1164_slash_rccm__201802___0356oc-337-53-59?v=Cayman+Chemical
    Average 90 stars, based on 1 article reviews
    fibronectin binding inhibitor rgds peptide - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or RGDS peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.

    Journal: iScience

    Article Title: Role of pericytes in the development of cerebral cavernous malformations.

    doi: 10.1016/j.isci.2022.105642

    Figure Lengend Snippet: Figure 5. Blockage of fibronectin could rescue CCM lesions (A) Representative images of H&E and immunohistochemistry (IHC) staining of Ccm1fl/fland Ccm1ECKO mice at age P14 treated with vehicle or RGDS peptide. The cyan boxes marked the staining of fibrinogen and CD41 which were negative in cerebellum of Ccm1fl/flmice. The blue boxes marked CCM lesions with thrombus which was fibrinogen and CD41 positive; the black boxes indicated CCM lesions without thrombus which was fibrinogen and CD41 negative. Scale bar: 200 mm. (B and C) The semiquantitative results of total CCM lesion number and area of cerebella in (A). The number and area of CCM lesions were quantified according to the area of < 5000 mm2, 5000–10000 mm2, or > 10000 mm2 (B), and according to CCM lesions with (stage II) or without thrombus (stage I) (C). (D) Representative confocal microscopy images of the retina in Ccm1ECKO and Ccm1fl/flmice. The whole-mount staining of retinas was performed using isolectin B4. The white dotted line marked CCM lesions. Scale bar: 500 mm. (E) Quantification of retinal lesion area in Ccm1ECKO mice treated with or without RGDS peptide. n = 4 or 5 mice per group. Data are presented as mean G SD. *P < 0.05, **P < 0.01, unpaired Student’s t-test for upper panels of B, C, and E, one-way ANOVA with Tukey’s post-hoc test for bottom panels of B.

    Article Snippet: Ccm1fl/fl or Ccm1ECKO mice were also intraperitoneally injected with vehicle control or a specific fibronectin inhibitor RGDS peptide (5 mg/kg body weight, MCE, HY12290) from P5–P7 daily and P9–P13 every alternate day.

    Techniques: Immunohistochemistry, Staining, Confocal Microscopy